<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="UTF-8">
    <meta name="viewport" content="width=device-width, initial-scale=1.0">
    <title>34 Haematological aspects of systemic disease I: Inflammation—malignancy</title>
    <link href="https://fonts.googleapis.com/css2?family=Inter:wght@400;500;600;700&display=swap" rel="stylesheet">
    <link rel="stylesheet" href="../styles/main.css">
    <!-- Include MathJax -->
    <script>
    MathJax = {
        tex: {
            inlineMath: [['$', '$'], ['\\(', '\\)']],
            displayMath: [['$$', '$$'], ['\\[', '\\]']],
            processEscapes: true,
            processEnvironments: true,
            tags: 'ams' // Use AMS numbering of equations
        },
        svg: { fontCache: 'global' },
        options: {
            skipHtmlTags: ['script', 'noscript', 'style', 'textarea', 'pre']
        }
    };
    </script>
    <script src="https://polyfill.io/v3/polyfill.min.js?features=es6"></script>
    <script id="MathJax-script" async src="https://cdn.jsdelivr.net/npm/mathjax@3/es5/tex-mml-chtml.js"></script>
</head>
<body>
    <div class="container">
        <article class="document-section" role="main">
            <!-- Top Navigation -->
            <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-33-anticoagulation.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 85%;"></div>
                        </div>
                       <span class="progress-text">Lecture 34 of 40</span>
                    </div>
                    <a href="haematology-35-haematological-aspects-of-systemic-disease-II.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

            <header class="section-header">
                <h1 class="section-title">34 Haematological aspects of systemic disease I: Inflammation—malignancy</h1>
                <div class="title-underline"></div>
            </header>

            <main class="section-content">
                
                <section id="intro" class="content-section" aria-labelledby="section-heading-1">
                    <div class="content-card">
                        <p>A wide range of abnormalities affecting red cells, white cells, platelets and coagulation factors occur in association with systemic illness.</p>
                    </div>
                </section>

                <section id="anaemia-of-chronic-disease" class="content-section" aria-labelledby="section-heading-2">
                    <h2 id="section-heading-2" class="section-heading">
                        <span class="heading-text">Anaemia of chronic disease</span>
                    </h2>
                    <div class="content-card">
                        <ul>
                            <li>Anaemia of chronic disease (ACD) is a common normochromic or mildly hypochromic anaemia, occurring in patients with a systemic disease (Table 34.1). Moderate anaemia occurs (haemoglobin level &gt;9.0 g/dL, severity of anaemia correlating with severity of underlying disease).</li>
                            <li>Reduced serum iron and total iron binding capacity.</li>
                            <li>Normal or raised serum ferritin with adequate iron stores in the bone marrow but stainable iron absent from erythroblasts.</li>
                        </ul>
                        
                        <h3 class="subsection-heading">Pathogenesis</h3>
                        <p>Increased levels of cytokines, especially IL-1, IL-6, tumour necrosis factor and interferon-$\gamma$, which interact with accessory marrow stromal cells, macrophages and erythroid progenitors to reduce erythropoiesis, iron utilization and response to erythropoietin (EPO).</p>
                        
                        <h3 class="subsection-heading">Treatment</h3>
                        <ul>
                            <li>Therapy of the chronic disease gradually reduces levels of mediator cytokines.</li>
                            <li>Recombinant EPO may improve anaemia in patients with, for example, rheumatoid arthritis (RA), cancer and myeloma.</li>
                        </ul>

                        <div class="table-container">
                            <table class="content-table">
                                <caption>Table 34.1 Conditions associated with anaemia of chronic disorders.</caption>
                                <tbody>
                                    <tr><td><strong>Chronic infections</strong></td></tr>
                                    <tr><td>Especially osteomyelitis, bacterial endocarditis, tuberculosis, chronic abscesses, bronchiectasis, chronic urinary tract infections, HIV, AIDS, malaria</td></tr>
                                    <tr><td><strong>Other chronic inflammatory disorders</strong></td></tr>
                                    <tr><td>Rheumatoid arthritis, polymyalgia rheumatica, systemic lupus erythematosus, scleroderma, inflammatory bowel disease, thrombophlebitis</td></tr>
                                    <tr><td><strong>Malignant diseases</strong></td></tr>
                                    <tr><td>Carcinoma, especially metastatic or associated with infection, lymphoma</td></tr>
                                    <tr><td><strong>Others</strong></td></tr>
                                    <tr><td>Congestive heart failure, ischaemic heart disease</td></tr>
                                </tbody>
                            </table>
                        </div>
                    </div>
                </section>

                <section id="malignancy" class="content-section" aria-labelledby="section-heading-3">
                    <h2 id="section-heading-3" class="section-heading">
                        <span class="heading-text">Malignancy</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Anaemia</h3>
                        <ul>
                            <li>Anaemia of chronic disease affects almost all cancer patients at some stage.</li>
                            <li>Blood loss in gastrointestinal and gynaecological malignancies.</li>
                            <li>Autoimmune haemolytic anaemia (AIHA), especially in lymphoma.</li>
                            <li>Microangiopathic haemolytic anaemia (see Chapter 15) may occur with disseminated mucin-secreting adenocarcinoma.</li>
                            <li>Leuco-erythroblastic anaemia indicates marrow infiltration by tumour (Fig. 34.1).</li>
                            <li>Red cell aplasia is associated with thymoma, lymphoma and chronic lymphocytic leukaemia.</li>
                        </ul>

                        <h3 class="subsection-heading">Other causes</h3>
                        <p>Chemotherapy or radiotherapy-induced inhibition of bone marrow. Folate deficiency as a result of poor diet and widespread disease.</p>
                        
                        <h3 class="subsection-heading">Polycythaemia</h3>
                        <p>Tumour cells may produce EPO or EPO-like peptides in renal cell carcinoma, hepatoma and uterine myoma (see Chapter 27).</p>
                        
                        <h3 class="subsection-heading">White cell changes</h3>
                        <p>Cancer patients frequently have opportunistic infections or bleed, which raises white cells (usually neutrophils), or receive chemotherapy or radiotherapy, which lowers them.</p>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-093-1.jpg" alt="Fig. 34.1 Leuco-erythroblastic blood film showing circulating immature granulocytes and nucleated red blood cells, indicating marrow infiltration." class="content-image">
                            <figcaption>Fig. 34.1 Leuco-erythroblastic blood film showing circulating immature granulocytes and nucleated red blood cells indicating in this case marrow infiltration.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-094-1.jpg" alt="Fig. 34.2 Bone marrow aspirate showing infiltration by breast carcinoma cells." class="content-image">
                            <figcaption>Fig. 34.2 Secondary carcinoma: bone marrow aspirate showing infiltration by breast carcinoma.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-094-2.jpg" alt="Fig. 34.3 Bone marrow aspirate with immunocytochemistry showing positive staining for cytokeratin in breast carcinoma cells." class="content-image">
                            <figcaption>Fig. 34.3 Secondary carcinoma: bone marrow aspirate immunocytochemistry showing positive staining for cytokeratin in breast carcinoma cells.</figcaption>
                        </figure>

                        <figure>
                            <img src="../assets/images/2025_09_09_3fc5c60a4aba104b7634g-094-3.jpg" alt="Fig. 34.4 Bone marrow trephine biopsy showing secondary carcinoma from a prostatic primary." class="content-image">
                            <figcaption>Fig.34.4 Bone marrow trephine biopsy showing secondary carcinoma (prostatic).</figcaption>
                        </figure>
                        
                        <h3 class="subsection-heading">Platelets</h3>
                        <p>Thrombocytopenia may be due to decreased production (e.g. extensive marrow infiltration, chemotherapy or radiotherapy), accelerated peripheral destruction (e.g. disseminated intravascular coagulation, DIC) and/or hypersplenism (Figs 34.2-34.4). Immune thrombocytopenia may occur especially with lymphoma.</p>
                        <p>Thrombocytosis is a frequent reactive phenomenon in malignancy.</p>
                        
                        <h3 class="subsection-heading">Coagulation changes</h3>
                        <p>Activation of both coagulation and fibrinolysis may predispose to either haemorrhage or thrombosis. Chronic DIC (e.g. with pancreatic carcinoma) causes thrombosis, including migratory thrombophlebitis (Trousseau's syndrome). Circulating anticoagulants (e.g. acquired von Willebrand factor inhibitors) and specific coagulation factor inhibitors may occur.</p>
                    </div>
                </section>

                <section id="connective-tissue-disorders" class="content-section" aria-labelledby="section-heading-4">
                    <h2 id="section-heading-4" class="section-heading">
                        <span class="heading-text">Connective tissue disorders</span>
                    </h2>
                    <div class="content-card">
                        <h3 class="subsection-heading">Anaemia</h3>
                        <ul>
                            <li>Anaemia of chronic disease is common. Iron deficiency may coexist in patients with gastrointestinal haemorrhage caused by non-steroidal anti-inflammatory agents.</li>
                            <li>Autoimmune haemolytic anaemia occurs in systemic lupus erythematosus (SLE), RA and mixed connective tissue disorders (CTD).</li>
                            <li>Red cell aplasia occurs in SLE.</li>
                        </ul>
                        
                        <h3 class="subsection-heading">White cells</h3>
                        <p>Inflammation leads to neutrophilia. Neutropenia with splenomegaly occurs in patients with RA (Felty's syndrome). Antibody and immune-complex mediated neutrophil destruction and decreased neutrophil production in the marrow may also occur in SLE. Eosinophilia may occur in SLE, RA and polyarteritis nodosa.</p>
                        
                        <h3 class="subsection-heading">Platelets</h3>
                        <p>Thrombocytopenia may be immune (SLE, rather than scleroderma and RA). Thrombocytosis is a non-specific reactive phenomenon to inflammation in CTD.</p>
                        
                        <h3 class="subsection-heading">Coagulation changes</h3>
                        <p>These may be caused by associated renal disease, drug therapy, DIC and specific coagulation factor inhibitors. The lupus anticoagulant occurs in approximately 10% of patients with SLE (see Chapter 32).</p>
                    </div>
                </section>

            </main>

            <!-- Bottom Navigation -->
             <nav class="document-nav" role="navigation" aria-label="Document Sections">
                <div class="nav-links">
                    <a href="../index.html" class="nav-button">
                        <span class="nav-icon"></span>
                        <span class="nav-text">Table of Contents</span>
                    </a>
                    <a href="haematology-33-anticoagulation.html" class="nav-button">
                        <span class="nav-icon">←</span>
                        <span class="nav-text">Previous Section</span>
                    </a>
                    <div class="document-progress">
                         <div class="progress-bar" aria-hidden="true">
                            <div class="progress-fill" style="width: 85%;"></div>
                        </div>
                       <span class="progress-text">Lecture 34 of 40</span>
                    </div>
                    <a href="haematology-35-haematological-aspects-of-systemic-disease-II.html" class="nav-button">
                        <span class="nav-text">Next Section</span>
                        <span class="nav-icon">→</span>
                    </a>
                </div>
            </nav>

        </article>
    </div>
    <script src="../js/navigation.js"></script>
</body>
</html>